NCI Archives
Probiotic protection
Mar. 4, 2021—A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease.
Potential biomarker for IBD severity, cancer risk identified
Feb. 4, 2021—A selenium transport protein produced in the colon may be a novel biomarker for assessing disease severity and cancer risk in patients with inflammatory bowel disease.
Gene network for leukemia factor
Feb. 4, 2021—A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.
An interacting factor in leukemia
Jan. 25, 2021—A blood stem cell protein plays a role in the initiation and progression of leukemia, Vanderbilt researchers have found.
WIN for blocking cancer growth
Jan. 21, 2021—William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.
Vitamin D activation and cancer risk
Jan. 7, 2021—Vitamin D protection against colon cancer varies according to parathyroid hormone response, particularly among women.
Study reveals new strategy for reducing tumor growth, metastasis
Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
New therapeutic target for lung cancer
Nov. 12, 2020—Vanderbilt researchers have identified a new molecular partner — and potential therapeutic target — in a signaling axis that drives lung cancer.
New markers of colorectal cancer risk
Oct. 29, 2020—Vanderbilt epidemiologists identified new markers for colorectal cancer risk and characterized a previously unidentified tumor suppressor that regulates overall tumor volume in vivo.
Preserving gut mucus architecture
Oct. 20, 2020—A new method that keeps microbes and gut cells together will be useful for studies of complex host-microbe interactions and for analysis of clinical specimens.
Possible COVID-19 “decoy”
Oct. 15, 2020—It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.
VICC receives ‘exceptional’ score with renewal as an NCI-Designated Comprehensive Cancer Center
Sep. 29, 2020—Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.
